MX2018008106A - Terapias con celulas inmunoefectoras de una eficacia mejorada. - Google Patents
Terapias con celulas inmunoefectoras de una eficacia mejorada.Info
- Publication number
- MX2018008106A MX2018008106A MX2018008106A MX2018008106A MX2018008106A MX 2018008106 A MX2018008106 A MX 2018008106A MX 2018008106 A MX2018008106 A MX 2018008106A MX 2018008106 A MX2018008106 A MX 2018008106A MX 2018008106 A MX2018008106 A MX 2018008106A
- Authority
- MX
- Mexico
- Prior art keywords
- immune effector
- effector cell
- cell therapies
- enhanced efficacy
- cells
- Prior art date
Links
- 239000012642 immune effector Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 238000002659 cell therapy Methods 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Se proporciona el uso de inhibidores de LSD1 en relación con el uso y la elaboración de células inmunoefectoras (por ejemplo, células T, células NK). por ejemplo, que se diseñan para expresar un receptor de antígeno quimérico (CAR), con el fin de tratar a un sujeto que tenga una enfermedad, por ejemplo, una enfermedad asociada con la expresión de un antígeno de tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015099882 | 2015-12-30 | ||
PCT/CN2016/113612 WO2017114497A1 (en) | 2015-12-30 | 2016-12-30 | Immune effector cell therapies with enhanced efficacy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018008106A true MX2018008106A (es) | 2019-03-14 |
Family
ID=59224653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008106A MX2018008106A (es) | 2015-12-30 | 2016-12-30 | Terapias con celulas inmunoefectoras de una eficacia mejorada. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190000880A1 (es) |
EP (2) | EP4219689A3 (es) |
JP (1) | JP2019500394A (es) |
KR (1) | KR20180099768A (es) |
CN (1) | CN109072195A (es) |
AU (1) | AU2016382512A1 (es) |
BR (1) | BR112018013074A2 (es) |
CA (1) | CA3009709A1 (es) |
ES (1) | ES2944597T3 (es) |
IL (2) | IL260269B (es) |
MX (1) | MX2018008106A (es) |
RU (1) | RU2018127657A (es) |
SG (1) | SG11201805451TA (es) |
WO (1) | WO2017114497A1 (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
ES2805475T3 (es) | 2014-07-21 | 2021-02-12 | Novartis Ag | Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33 |
KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
MX2017003645A (es) | 2014-09-17 | 2017-05-30 | Novartis Ag | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US10253086B2 (en) | 2015-04-08 | 2019-04-09 | Novartis Ag | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell |
CN108473957A (zh) | 2015-04-17 | 2018-08-31 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
EP3344996A2 (en) | 2015-09-03 | 2018-07-11 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
WO2018045422A1 (en) * | 2016-09-07 | 2018-03-15 | University Of Canberra | Lysine specific histone demethylase-1 inhibitors and uses therefor |
US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
EP3523290A4 (en) * | 2016-09-30 | 2020-07-29 | Novartis AG | IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES |
EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
KR20190130608A (ko) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | 면역종양학을 위한 조성물 및 방법 |
EP3638260A1 (en) | 2017-07-21 | 2020-04-22 | Cellectis | Engineered immune cells resistant to tumor microoenvironment |
WO2019016360A1 (en) * | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
BR112020000827A2 (pt) | 2017-08-03 | 2020-07-21 | Oryzon Genomics, S.A. | métodos de tratamento de alterações de comportamento |
WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
WO2019100079A1 (en) * | 2017-11-20 | 2019-05-23 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Compositions for improving car-t cell functionality and user thereof |
WO2019165237A1 (en) * | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
CN108753773B (zh) * | 2018-05-03 | 2021-03-30 | 山东省齐鲁细胞治疗工程技术有限公司 | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 |
MX2020013443A (es) | 2018-06-13 | 2021-02-26 | Novartis Ag | Receptores de antigeno quimerico de bcma y usos de los mismos. |
WO2019246546A1 (en) * | 2018-06-22 | 2019-12-26 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
WO2020061796A1 (en) * | 2018-09-26 | 2020-04-02 | Hrain Biotechnology Co., Ltd. | Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof |
CN113573778A (zh) * | 2018-11-16 | 2021-10-29 | 拉帕治疗有限公司 | 使用诱导性调节性T(iTREG)细胞进行的ALS治疗 |
WO2020146345A1 (en) * | 2019-01-07 | 2020-07-16 | Children's Medical Center Corporation | Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy |
JP2022519649A (ja) | 2019-02-08 | 2022-03-24 | ジェネンテック, インコーポレイテッド | がんの診断および治療方法 |
SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
WO2020188089A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
US20200323905A1 (en) * | 2019-04-15 | 2020-10-15 | Trustees Of Boston University | Methods and compositions for modulating the immune system |
WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
CN110627903B (zh) * | 2019-10-29 | 2021-09-21 | 河南大学 | 抗cd97单克隆抗体、其可变区与恒定区序列及应用 |
KR20220104217A (ko) | 2019-11-26 | 2022-07-26 | 노파르티스 아게 | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 |
EP3904507A1 (en) * | 2020-04-28 | 2021-11-03 | Ospedale San Raffaele S.r.l. | Method to produce t cells and uses thereof |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
CN113667021B (zh) * | 2020-12-14 | 2022-03-29 | 广州百暨基因科技有限公司 | 靶向b7h3的嵌合抗原受体及其应用 |
AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック, インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Cd19和cd22嵌合抗原受體及其用途 |
WO2023073062A1 (en) * | 2021-10-26 | 2023-05-04 | Universite Paris-Saclay | T cell immunotherapy derived from highly functional autologous stem |
CN114410689B (zh) * | 2022-03-29 | 2022-06-17 | 北京循生生物医学研究有限公司 | 一种增强肿瘤浸润淋巴细胞杀伤力的制备方法 |
WO2023220012A1 (en) * | 2022-05-11 | 2023-11-16 | Mayo Foundation For Medical Education And Research | Treating cancer |
WO2023225634A2 (en) * | 2022-05-20 | 2023-11-23 | Imago Biosciences, Inc. | Methods for the enhancement of therapeutic effect of car-t cells |
CN115612673A (zh) * | 2022-12-14 | 2023-01-17 | 卡瑞济(北京)生命科技有限公司 | 一种改善car-t细胞群的持久性的方法 |
Family Cites Families (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US5504048A (en) | 1993-06-02 | 1996-04-02 | Fina Technology, Inc. | Addition of lithium compounds to Ziegler-Natta catalysts for increased molecular weight in polyolefins |
WO1995014042A1 (fr) | 1993-11-16 | 1995-05-26 | Pola Chemical Industries Inc. | Anticorps monoclonal anti-tyrosinase humaine |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
JPH10505481A (ja) | 1994-04-22 | 1998-06-02 | アメリカ合衆国 | メラノーマ抗原 |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
CA2210620C (en) | 1995-01-18 | 2004-06-22 | Boehringer Mannheim Gmbh | Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6083502A (en) | 1996-01-05 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelium antigen and methods and kits for targeting it |
DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
JP2001510987A (ja) | 1996-10-25 | 2001-08-07 | アメリカ合衆国 | 哺乳動物のCD97αサブユニットを含む炎症および脈管形成を阻害するための方法および組成物 |
DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
ES2255194T3 (es) | 1997-12-01 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos, que incluyen moleculas fv, e inmunoconjugados que presentan una afinidad de enlace elevada para la mesotelina y metodos para su utilizacion. |
US6183608B1 (en) | 1998-02-05 | 2001-02-06 | Wilbur A. Dammann | Electrode positioning mechanism |
US6803448B1 (en) | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
EE05673B1 (et) | 1999-08-17 | 2013-08-15 | Biogen, Inc. | BAFF-retseptor (BCMA), immunoregulatoorne agens |
CA2386197A1 (en) | 1999-09-30 | 2001-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Complementarity determining region-grafted antibody against ganglioside gd3 and derivative of antibody against ganglioside gd3 |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
JP2004509835A (ja) | 2000-03-06 | 2004-04-02 | ユニヴァーシティ オブ ケンタッキー リサーチ ファンデーション | 血液癌前駆細胞を障害する方法およびその関連化合物 |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
US8298769B2 (en) | 2001-08-23 | 2012-10-30 | Rsr Limited | Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto |
AU2002351239A1 (en) | 2001-12-04 | 2003-06-17 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20040106904A1 (en) | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
JP4744147B2 (ja) | 2002-11-26 | 2011-08-10 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | アフィニティー精製抗体を用いた甲状腺刺激ホルモン受容体自己抗体の同定 |
WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
US7479546B2 (en) | 2003-06-27 | 2009-01-20 | Diadexus, Inc. | Pro104 antibody compositions and methods of use |
JP5026072B2 (ja) | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | 二重特異性抗体の多価キャリヤー |
WO2005014652A1 (en) | 2003-08-05 | 2005-02-17 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
WO2005035577A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ガングリオシドgd3に特異的に結合する抗体組成物 |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
AU2006259536A1 (en) | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
BRPI0614805A2 (pt) | 2005-08-10 | 2011-04-12 | Univ Johns Hopkins | poliaminas úteis como produtos terapêuticos antiparasìticos e anticáncer e como inibidores de demetilase lisina-especìficos |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
EA017491B1 (ru) | 2005-12-08 | 2012-12-28 | Медарекс, Инк. | Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
US8603466B2 (en) | 2006-03-29 | 2013-12-10 | King's College London | Agonist antibodies against TSHR |
TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之c-kit抗體 |
JP2010505775A (ja) | 2006-10-04 | 2010-02-25 | クーベンハヴンス・ユニヴェルシテット | Muc1に対する癌特異的な免疫反応の産生及び癌特異的muc1抗体 |
FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
WO2008101234A2 (en) | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
US7635753B2 (en) | 2007-02-19 | 2009-12-22 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
US20100158927A1 (en) | 2007-03-29 | 2010-06-24 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | IL13Ra2に対する抗体およびこれを含む診断・治療薬 |
WO2009017679A2 (en) | 2007-07-31 | 2009-02-05 | Merck & Co., Inc. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
EA018396B1 (ru) | 2007-10-01 | 2013-07-30 | Бристоль-Мейерз Сквибб Компани | Антитела человека, которые связывают мезотелин, и применение таких антител |
EP2215121B1 (en) | 2007-11-26 | 2016-02-10 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
JP2012503203A (ja) | 2008-09-19 | 2012-02-02 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 基底乳癌腫の診断および処置のためのcspg4に対するモノクローナル抗体 |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
KR101732201B1 (ko) | 2009-04-27 | 2017-05-02 | 교와 핫꼬 기린 가부시키가이샤 | 혈액 종양 치료를 목적으로 하는 항IL-3Rα 항체 |
US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
BR112012012887A2 (pt) | 2009-12-02 | 2017-05-02 | Imaginab Inc | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. |
WO2011076922A1 (en) | 2009-12-23 | 2011-06-30 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
RU2740479C2 (ru) | 2010-02-24 | 2021-01-14 | Иммьюноджен, Инк. | Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование |
WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
CA2801210C (en) | 2010-06-19 | 2020-07-21 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
NZ612512A (en) | 2010-12-09 | 2015-03-27 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
WO2012107499A1 (en) * | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
MY165620A (en) | 2011-03-25 | 2018-04-18 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
EA201391449A1 (ru) | 2011-04-01 | 2014-03-31 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Антитела против пептидов цитозоля |
PT3459560T (pt) | 2011-04-08 | 2021-05-24 | Us Health | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro |
AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
PL3415531T3 (pl) | 2011-05-27 | 2024-02-26 | Glaxo Group Limited | Białka wiążące antygen |
CA2848410A1 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
ES2716298T3 (es) | 2011-09-16 | 2019-06-11 | Baylor College Medicine | El microentorno tumoral como diana mediante el uso de células NKT manipuladas |
DE102011114180A1 (de) | 2011-09-22 | 2013-03-28 | Weber Maschinenbau Gmbh Breidenbach | Vorrichtung zum Aufschneiden von einem Lebensmittelprodukt und Vorrichtung mit einem Roboter |
FR2980528B1 (fr) | 2011-09-22 | 2013-08-30 | IFP Energies Nouvelles | Procede de controle de la combustion d'un moteur a combustion interne a injection directe d'essence, notamment a allumage commande |
CN103958474B (zh) | 2011-10-20 | 2017-03-08 | 奥莱松基因组股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙基胺化合物 |
CN104203914B (zh) | 2011-10-20 | 2017-07-11 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
ITMO20110270A1 (it) | 2011-10-25 | 2013-04-26 | Sara Caldrer | Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2 |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
US9439768B2 (en) | 2011-12-08 | 2016-09-13 | Imds Llc | Glenoid vault fixation |
EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
EP2844300B1 (en) | 2012-05-01 | 2018-10-17 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
WO2013173820A2 (en) | 2012-05-18 | 2013-11-21 | Scott & White Healthcare | Bispecific scfv immunofusion (bif) |
PE20190844A1 (es) | 2012-05-25 | 2019-06-17 | Emmanuelle Charpentier | Modulacion de transcripcion con arn de direccion a adn generico |
WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
KR20230065381A (ko) | 2012-07-25 | 2023-05-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유도 dna 결합 단백질 및 게놈 교란 도구 및 이의 적용 |
CA3177394A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
US10316289B2 (en) * | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
ES2701749T3 (es) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP3045537A1 (en) | 2012-12-12 | 2016-07-20 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
WO2014093635A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
CN113528577A (zh) | 2012-12-12 | 2021-10-22 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
EP4299741A3 (en) | 2012-12-12 | 2024-02-28 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
CN114634950A (zh) | 2012-12-12 | 2022-06-17 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
WO2014138819A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Agents that neutralize il-3 signaling and uses thereof |
WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
CA3185368A1 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t cells derived from pluripotent stem cells |
CA2913869C (en) | 2013-05-29 | 2023-01-24 | Cellectis | New compact scaffold of cas9 in the type ii crispr system |
DK3011029T3 (da) | 2013-06-17 | 2020-03-16 | Broad Inst Inc | Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering |
WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
EP4245853A3 (en) | 2013-06-17 | 2023-10-18 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
BR112015031611A2 (pt) | 2013-06-17 | 2017-12-12 | Massachusetts Inst Technology | aplicação, manipulação e otimização de sistemas, métodos e composições para direcionamento e modelação de doenças e distúrbios de células pós-mitóticas |
EP3011031B1 (en) | 2013-06-17 | 2020-09-30 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
MX2015017313A (es) | 2013-06-17 | 2016-11-25 | Broad Inst Inc | Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos. |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
SG10201710543PA (en) | 2013-06-19 | 2018-02-27 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
AU2014296059B2 (en) * | 2013-08-02 | 2020-12-10 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3119423B1 (en) | 2014-03-15 | 2022-12-14 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
BR112016022345A2 (pt) * | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
IL280215B (en) | 2014-04-07 | 2022-07-01 | Novartis Ag | Cancer treatment using a chimeric receptor antigen (car) against cd19 |
MX2016013369A (es) | 2014-04-11 | 2017-02-09 | Takeda Pharmaceuticals Co | Compuesto de ciclopropanamina y sus usos. |
WO2015181380A1 (en) * | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
ES2805475T3 (es) | 2014-07-21 | 2021-02-12 | Novartis Ag | Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33 |
KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
AU2015292590B2 (en) | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2016210292A1 (en) * | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
WO2017161001A1 (en) * | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
EP3523290A4 (en) * | 2016-09-30 | 2020-07-29 | Novartis AG | IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES |
-
2016
- 2016-12-30 JP JP2018534665A patent/JP2019500394A/ja active Pending
- 2016-12-30 EP EP23152887.8A patent/EP4219689A3/en active Pending
- 2016-12-30 CA CA3009709A patent/CA3009709A1/en not_active Abandoned
- 2016-12-30 MX MX2018008106A patent/MX2018008106A/es unknown
- 2016-12-30 CN CN201680082866.9A patent/CN109072195A/zh active Pending
- 2016-12-30 US US16/066,855 patent/US20190000880A1/en active Pending
- 2016-12-30 EP EP16881286.5A patent/EP3397756B1/en active Active
- 2016-12-30 RU RU2018127657A patent/RU2018127657A/ru not_active Application Discontinuation
- 2016-12-30 ES ES16881286T patent/ES2944597T3/es active Active
- 2016-12-30 KR KR1020187021451A patent/KR20180099768A/ko unknown
- 2016-12-30 SG SG11201805451TA patent/SG11201805451TA/en unknown
- 2016-12-30 BR BR112018013074A patent/BR112018013074A2/pt active Search and Examination
- 2016-12-30 AU AU2016382512A patent/AU2016382512A1/en not_active Abandoned
- 2016-12-30 WO PCT/CN2016/113612 patent/WO2017114497A1/en active Application Filing
-
2018
- 2018-06-25 IL IL260269A patent/IL260269B/en unknown
-
2021
- 2021-09-09 IL IL286207A patent/IL286207A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3009709A1 (en) | 2017-07-06 |
BR112018013074A2 (pt) | 2018-12-11 |
EP4219689A2 (en) | 2023-08-02 |
US20190000880A1 (en) | 2019-01-03 |
IL260269A (en) | 2018-07-31 |
KR20180099768A (ko) | 2018-09-05 |
CN109072195A (zh) | 2018-12-21 |
JP2019500394A (ja) | 2019-01-10 |
AU2016382512A1 (en) | 2018-07-12 |
EP4219689A3 (en) | 2023-12-20 |
IL260269B (en) | 2021-09-30 |
RU2018127657A3 (es) | 2020-10-16 |
WO2017114497A1 (en) | 2017-07-06 |
EP3397756B1 (en) | 2023-03-08 |
RU2018127657A (ru) | 2020-01-31 |
IL286207A (en) | 2021-10-31 |
EP3397756A4 (en) | 2019-12-04 |
EP3397756A1 (en) | 2018-11-07 |
SG11201805451TA (en) | 2018-07-30 |
ES2944597T3 (es) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008106A (es) | Terapias con celulas inmunoefectoras de una eficacia mejorada. | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
EP3307282A4 (en) | TREATMENT OF DISEASES WITH CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (T-CAR) OR NK (CAR-NK) CELL EXPRESSION CONSTRUCTIONS CAR CONSTRUCTIONS | |
MX2017000646A (es) | Celulas geneticamente modificadas para terapia celular adoptiva. | |
MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
HK1215583A1 (zh) | 靶向於不同的多種抗原的通用嵌合抗原受體表達免疫細胞及其生產方法及其用於治療癌症、感染和自身免疫障礙的用途 | |
MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
TW201614072A (en) | CAR-T lymphocytes engineered to home to lymph node B cell zone, skin, or gastrointestinal tract | |
WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
PH12015502126A1 (en) | Human pac1 antibodies | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
PH12016500753B1 (en) | Antibodies specific to fcrn | |
AU2018341227A1 (en) | Tissue factor-targeting CAR-NK and CAR-T cell therapy | |
NZ770578A (en) | Methods and compositions for adoptive cell therapy | |
NZ751761A (en) | Compositions and methods for immunotherapy |